Skip to content
Suraksha Diagnostic logo

Suraksha Diagnostic

SURAKSHA NSE
₹333.05 +9.35 (+2.89%)
P/E
48.41
View as Markdown
MCP
Close 4 Nov 2026 ₹333.05 +8.25 +2.54% 1Y
Start ₹324.80

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.30%
Debt to Equity
0.53
EPS (TTM)
₹6.88
Book Value
₹47.01
Market Cap
—
P/E (TTM)
48.41
P/B
7.08
ROE
14.20%
Dividend Yield
0.15%
EBITDA
₹98.60 Cr
52W High
₹360.00
52W Low
₹224.10
Day Range
₹324.30 – ₹336.00
Volume
48,123

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Suraksha Diagnostic peer comparison
Dr Lal Pathlabs
₹2,029.4062.75₹32,036 Cr13.580.26%22.30%28.00%₹2,891 Cr₹545 Cr
Vijaya Diagnostic Centre
₹1,424.6078.15₹14,588 Cr15.330.14%18.30%20.50%₹857 Cr₹187 Cr
Metropolis Healthcare
₹581.2559.74₹11,437 Cr8.030.88%13.60%17.80%₹1,710 Cr₹203 Cr
Thyrocare Technologies
₹495.5044.72₹7,723 Cr14.252.90%28.40%35.40%₹876 Cr₹176 Cr
Nephrocare Health Services
₹622.35148.53₹5,903 Cr5.610.00%8.83%15.30%₹1,053 Cr₹85 Cr
Suraksha Diagnostic (this company)
₹333.0548.41₹1,717 Cr7.080.15%14.20%17.30%₹325 Cr₹35 Cr
Krsnaa Diagnostics
₹483.0515.84₹1,571 Cr1.510.41%10.90%12.70%₹726 Cr₹98 Cr
Median 7 companies₹581.2559.74₹7,723 Cr8.030.26%14.20%17.80%₹876 Cr₹176 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

Category scores

Quality
61
Good
Returns, margins, earnings quality 22% weight
Valuation
37
Weak
Cheap vs sector & own history 24% weight
Growth
79
Strong
Sales & profit trajectory 9% weight
Financial Health
38
Weak
Solvency, leverage, coverage 9% weight
Momentum
53
Average
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 31.8% CAGR over last 5 years

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBearish342
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
59.13
Neutral
MACD (12,26,9)
−0.40
Bullish
SMA (50)
327.78
Bullish
SMA (200)
286.92
Bullish

As of

Analyst Rating

Based on 1 analysts
HOLD100%

0 of 1 analyst rates Buy, 1 Hold, 0 Sell.

As of

BUY
0
0%
HOLD
1
100%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+17.23%
3Y+17.73%
1Y+23.02%
TTM+23.02%

Net profit

Net profit growth by window
5Y+38.88%
3Y+72.88%
1Y0.00%
TTM+9.38%

Operating cash flow

Operating cash flow growth by window
5Y+27.86%
3Y+23.06%
1Y+30.16%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+13.11 pp
3Y+6.23 pp
1Y−1.57 pp
TTM−0.72 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹158 Cr
Mar 2021₹140 Cr
Mar 2022₹223 Cr
Mar 2023₹190 Cr
Mar 2024₹219 Cr
Mar 2025₹252 Cr
Mar 2026₹310 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹15.00 Cr
Mar 2021₹6.00 Cr
Mar 2022₹24.00 Cr
Mar 2023₹6.00 Cr
Mar 2024₹23.00 Cr
Mar 2025₹31.00 Cr
Mar 2026₹31.00 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹118 Cr +20.0% vs FY26
Reported High Mean Low

Quarterly Results

₹ Cr
SURAKSHA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
60
52
55
61
67
60
65
73
79
78
81
88
Expenses
39
36
36
40
44
41
46
49
55
55
57
57
Operating Profit
21
15
19
21
23
18
19
24
24
23
24
30
OPM %
35%
30%
35%
34%
35%
31%
29%
33%
31%
30%
30%
35%
Other Income
1
1
0
1
1
1
1
1
1
1
1
1
Interest
2
2
2
2
2
2
2
3
3
3
4
4
Depreciation
8
8
8
9
9
9
9
9
10
11
11
11
PBT
11
6
9
11
14
8
9
12
12
10
10
17
Tax %
24%
27%
32%
27%
26%
26%
22%
26%
27%
28%
38%
22%
Net Profit
8
5
6
8
10
6
7
9
9
7
6
13
EPS (₹)
1.95
1.08
1.51
1.84
2.4
1.18
1.42
1.8
1.73
1.44
1.21
2.5

Profit & Loss

₹ Cr
SURAKSHA profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
158
140
223
190
219
252
310
325
Expenses
123
115
174
143
146
170
214
223
Operating Profit
34
25
49
47
73
82
96
102
OPM %
22%
18%
22%
25%
33%
33%
31%
31%
Other Income
2
−1
1
1
1
4
3
3
Interest
2
2
2
10
10
9
13
14
Depreciation
13
16
15
32
33
35
41
43
PBT
21
6
33
7
31
41
45
49
Tax %
28%
−1%
28%
10%
26%
25%
30%
—
Net Profit
15
6
24
6
23
31
31
35
EPS (₹)
3.53
1.49
5.51
1.51
5.48
6.11
6.18
6.88
Div. Payout %
0%
0%
0%
0%
0%
0%
1%
—

Balance Sheet

₹ Cr
SURAKSHA balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7
7
7
7
7
10
10
Reserves
111
118
141
147
171
201
234
Borrowings
13
18
21
99
92
89
130
Other Liabilities
42
28
32
28
30
33
73
Total Liabilities
173
171
201
281
300
334
448
Fixed Assets
128
119
119
195
212
223
315
CWIP
0
0
1
2
1
11
37
Investments
5
5
0
0
0
1
0
Other Assets
39
46
80
84
87
99
97
Total Assets
173
171
201
281
300
334
448

Cash Flow

₹ Cr
SURAKSHA cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
31
24
42
44
60
63
82
Investing
−20
−28
−44
−21
−35
−40
−52
Financing
−10
3
1
−24
−25
−24
−29
Net Cash Flow
1
−1
0
−1
0
0
1
Free Cash Flow
15
8
23
32
18
21
15
CFO/EBITDA
111
100
95
109
95
90
99

Ratios

SURAKSHA financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
14
16
12
9
15
20
27
Inventory Days
93
62
38
82
89
100
81
Days Payable
227
177
84
187
193
169
209
Cash Conversion Cycle
−120
−99
−34
−96
−89
−49
−101
Working Capital Days
−35
−19
−15
−49
−37
−23
−28
ROCE %
—
8%
24%
9%
17%
18%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Suraksha Diagnostic insights

60 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.10%
  • DIIs 21.56%
  • FIIs 13.97%
  • Public 11.64%
  • Others 3.73%

0.10% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Suraksha Diagnostic

What does Suraksha Diagnostic Ltd do?
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.
Where is Suraksha Diagnostic Ltd (SURAKSHA) listed?
Suraksha Diagnostic Ltd trades as SURAKSHA on the NSE and under code 544293 on the BSE.
Which sector does Suraksha Diagnostic Ltd belong to?
Suraksha Diagnostic Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the PE ratio of Suraksha Diagnostic Ltd?
Suraksha Diagnostic Ltd trades at a PE ratio of 48.41 as of 4 Nov 2026, on earnings per share of ₹6.88, against a book value of ₹47.01 per share.
What is the 52-week high and low of Suraksha Diagnostic Ltd?
Over the last 52 weeks Suraksha Diagnostic Ltd has traded between ₹224.1 and ₹360 as of 4 Nov 2026.
Does Suraksha Diagnostic Ltd pay dividends?
Suraksha Diagnostic Ltd has a dividend yield of 0.15%.
What is the Return on Equity (ROE) of Suraksha Diagnostic Ltd?
Suraksha Diagnostic Ltd reported a return on equity of 14.20%. Its debt-to-equity ratio is 0.53.

Company Information

Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.

Website surakshanet.com
Listed 6 Dec 2024
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SURAKSHA.md for Suraksha Diagnostic Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month